DiaMedica Therapeutics Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
DMAC on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Carlson Parkway, Suite 210, Minneapolis, MN

Insiders trading volume in the past year

DiaMedica Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Thomas Von Koch 10%+ Owner $13.8M +$3M +27.7% Jun 28, 2024
Jan Stahlberg 10%+ Owner $13.1M +$3M +29.8% Jun 28, 2024
Richard Jacinto II 10%+ Owner $12.8M Jun 23, 2023
David J. Wambeke Chief Business Officer $1.48M Jun 1, 2024
Randall Michael Giuffre Director $1.15M Jun 1, 2024
Richard D. Pilnik Director $780K Jun 1, 2024
Amy L. Burroughs Director $205K Jan 3, 2023
Dietrich John Pauls President and CEO, Director $192K Jun 1, 2024
James T. Parsons Director $168K Jun 1, 2024
Harry W. Alcorn Jr SVP, Clinical Operations $123K Sep 15, 2021
Charles Pauling Semba Director $110K Jun 1, 2024
Scott Kellen CFO and Secretary $90.4K Jun 1, 2024
Richard Kuntz Director $40K Jun 1, 2024
Dominic R. Cundari Chief Commercial Officer $7.84K Jun 1, 2024
Tanya Lewis Director $0 Jun 1, 2024
Masuoka K. Lorianne Chief Medical Officer Jan 22, 2024
Sydney A. Gilman VP, Regulatory Affairs Jul 28, 2021
Julie VanOrsdel Daves SVP Clinical Development Oper. Jun 1, 2023
Kirsten L. Gruis Chief Medical Officer Jun 1, 2023

Recent Insider Transactions by Companies or Individuals for DiaMedica Therapeutics Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.